Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		
iling Date		2006-03-23
irst Named Inventor Kirsch		hing et al.
Art Unit		
Examiner Name		
Homou Docket Numb	nr .	96293/9141

Examinor 140												
			Attorn	ey Doc	ket Numbe	er	86283/8141					
· · · · · · · · · · · · · · · · · · ·												
	U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	ssue Date  Name of Patentee or Applicant of cited Document			Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click t	the A	dd button.		Add		
			U.S.P	ATENT	APPLI	CATION P	JBLI	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>		Publication Name of Patentee or Applicant			Relev	Pages,Columns,Lines where Relevant Passages or Relevant rigures Appear			
	1											
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n informatio	on pl	ease click the Ad	d butto			
				FOREIG	SN PAT	ENT DOC	UME	NTS		Remove		
Examiner Initial*				Kind Code4	Publicatio Date	n	Name of Patente Applicant of cited Document	e or	where Rel	or Relevant	70	
	1	01/36488	wo		A1	2001-05-2	5	Lew Eiriksson Nyfe	otek			
	2	03/070761	wo		A1	2003-08-2		Yeda Research an Development Co. I				
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information	n ple	ase click the Add	button			
NON-PATENT LITERATURE DOCUMENTS Remove												

### Application Number Filing Date 2006-03-23 INFORMATION DISCLOSURE First Named Inventor Kirsching et al. STATEMENT BY APPLICANT Art I Init ( Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 86283/8141

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	ALIPRANTIS et al., "Cell Advartion and Apoptosis by Bacterial Lipoproleins Through Toll-like Receptor-2", Science, July 1999, 285.736-739	
	2	BRIGHTBILL et al., "Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-like Receptors", Science, July 1999, 265:732-736	
	3	MATSUGUCHI et al., "Gene Expressions of Lipopolysaccharide Receptors, Toll-like Receptors 2 and 4, are Differently Regulated in Mouse T Lymphocytes", Blood, Feb. 2000, 95(4):1378-1385	
	4	MENG et al., "Antagonistic Antibody Prevents Toll-like Receptor 2-driven Lethal Shock-like Syndromes", J Clin Invest., May 2004, 113(10):1473-1481	
	5	SANDOR et al., "Importance of Extra- and Intracellular Domains of TLR1 and TLR2 in NFkB Signaling", J Cell Biol., Sept. 2003,162(6):1099-1110	
	6	UEHORI et al., "Simultaneous Blocking of Human Toll-like Receptors 2 and 4 Suppresses Myeloid Dendritic Call Activation Induced by Mycobacterium bowls Bacillus Calmette-Guern Peptidoglycan", Infect Immun., Aug. 2003, 71 (8):4238-4249	

If you wish to add additional non-patent literature doc

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ocument citation information please click the Add button	/ tuu
EXAMINER SIGNATURE	

Date Considered \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO. Standard ST 3) 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if

Examiner Signature

English language translation is attached.

# Application Number Filing Date 2006-03-23 Filing Date 2006-03-23 First Number Interest Prince Interest Prince

### CERTIFICATION STATEMENT

i icuse see of	O1 11 1.07 u	na 1.55 to make	are appropriate	scicolonia).		

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/t).

# OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart to reign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Diagon one 37 CER 1 07 and 1 98 to make the appropriate colortion(c)

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David W. Maher/	Date (YYYY-MM-DD)	2006-03-23
Name/Print	David W. Maher	Registration Number	40.077

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.